Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Feingold

Internal Medicine Clearwater, FL Medical Doctor

NPI 1649221672 CMS profile 922481

516 Lakeview Rd Ste 4, Clearwater, FL 33756

Open in the dashboard

General payments

$4,148

222 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Howard Feingold of Clearwater, FL is reported in the CMS Open Payments database as having received $4,148 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $493 24
2024 General $680 32
2023 General $628 31
2022 General $759 41
2021 General $713 41
2020 General $519 30
2019 General $358 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Feingold
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Howard Feingold were reported at $493. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Howard Feingold Internal Medicine median Middle half National median
2019 $358 $159 $48–$570 $163
2020 $519 $119 $33–$402 $114
2021 $713 $135 $37–$521 $132
2022 $759 $141 $42–$496 $149
2023 $628 $149 $45–$519 $160
2024 $680 $154 $47–$537 $164
2025 $493 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $953 58 payments
  2. Novo Nordisk Inc $536 26 payments
  3. AbbVie, Inc. $396 17 payments
  4. Pfizer Inc. $341 18 payments
  5. Lilly USA, LLC $288 15 payments
  6. Amgen Inc. $277 16 payments
  7. Amarin Pharma Inc. $256 13 payments
  8. Janssen Pharmaceuticals, Inc $179 11 payments
  9. Merck Sharp & Dohme Corporation $119 7 payments
  10. Exact Sciences Corporation $115 5 payments
  11. Other $687 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,148 222 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $623 39 payments
  2. Ozempic $384 19 payments
  3. RYBELSUS $365 18 payments
  4. Vascepa $217 11 payments
  5. EVENITY $201 11 payments
  6. UBRELVY $200 9 payments
  7. XARELTO $179 11 payments
  8. AIRSUPRA $174 8 payments
  9. NURTEC ODT $155 7 payments
  10. Prolia $145 8 payments
  11. Other $2,788 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

5,208

Median for Internal Medicine: 777

Drug cost

$366,752

Median for Internal Medicine: $73,373

Branded share of claims

14.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 63 $84,225
Jardiance Empagliflozin Brand 50 $58,806
Eliquis Apixaban Brand 46 $44,969
Rybelsus Semaglutide Brand 22 $44,599
Xarelto Rivaroxaban Brand 37 $30,544
Ozempic Semaglutide Brand 17 $25,001
Januvia Sitagliptin Phosphate Brand 15 $12,822
Symbicort Budesonide/Formoterol Fumarate Brand 15 $5,643
Atorvastatin Calcium Generic 416 $4,182
Fluticasone Propionate Generic 146 $2,830

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$264,937

Of which drugs: $9,153

Medicare patients

415

Average age 79

Services billed

5,077

194 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 43%
Chronic kidney disease 30%
Diabetes 26%
Cancer 24%
Atrial fibrillation 23%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 110 110 $8,941

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $146
$146 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $75
$75 63 —
RYBELSUS
  • Novo Nordisk Inc $43
$43 22 —
Ozempic
  • Novo Nordisk Inc $43
$43 17 —
ZEPBOUND
  • Lilly USA, LLC $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record